Our mission is to support cutting edge science that will improve diagnostic and therapeutic strategies for our patients.  Please read more about clinical research studies at the Jill Roberts Center here.


 https://www.trustedtherapies.com/articles/78-joint-issues-related-to-crohn-s-disease-and-ulcerative-colitis

https://www.trustedtherapies.com/articles/78-joint-issues-related-to-crohn-s-disease-and-ulcerative-colitis

IBD-associated spondyloarthritis.  IBD-associated spondyloarthritis (SpA), which includes both axial spinal inflammation and peripheral joint manifestations of synovitis, dactylitis, and enthesitis, is one of the most common EIMs of IBD.  Peripheral manifestations alone carry a prevalence of 20% in CD and 10% in UC, predominantly affecting joints of the lower limbs.  Clinical evidence linking intestinal inflammation with SpA implicates the intestine as the source of aberrant systemic joint inflammation; however, a mechanistic understanding of the link between intestinal inflammation and SpA has yet to emerge.  Teaming up with renowned rheumatologists at the Hospital for Special Surgery, we are studying the connection between the intestinal bacteria and joint inflammation.  To read more please click here or contact us for more information. 


 Andrea Levy, The plain Dealer

Andrea Levy, The plain Dealer

Fecal Transplant for the Treatment of Mild to Moderate Ulcerative Colitis. Fecal microbiota transplantation (FMT) has proven safety and efficacy in the management of Clostridium difficile infection (CDI).  In collaboration with Drs. Vinita Jacob and Carl Crawford, we are currently conducting a study to test the safety and efficacy of FMT in the treatment of mild to moderate colitis.  Our laboratory is investigating the role for the microbiome in determining the efficacy and durability of this exciting new therapy. To read more please click here or contact us for more information. 


Roberts Institute Live Cell Bank.  Every patient at WCM has the opportunity to participate in the live cell bank.  This resource will enable us to characterize the microbiome, genetics, and immune cells from all participants and help achieve our mission to improve diagnostic and therapeutic options for IBD.   To read more please click here or contact us for more information.